Which LASA medication pair is a known risk, and what mitigation is recommended?

• A. Acetaminophen and ibuprofen; standard dosing alerts.
• B. Penicillin and amoxicillin; same class but not LASA.
• C. Levothyroxine and liothyronine; color-coded labeling.
• D. Hydrocodone vs hydromorphone; tall-man lettering, distinct labeling, separate storage, and clinician double-checks.

Answer: (D)

Look-alike/sound-alike drug names create the risk of giving the wrong medication, especially in busy settings where quick decisions are common. The strongest defenses are targeted safety measures for high-risk name pairs: tall-man lettering to highlight the differing parts of similar names, clear and distinct labeling, storing the two drugs separately, and requiring a clinician to double-check the choice before dispensing or administration. Hydrocodone and hydromorphone are a well-known LASA risk because their spellings and sounds are very similar, so a prescriber, pharmacist, or nurse could easily confuse one for the other. Using tall-man lettering helps people notice the difference in the names at a glance, distinct labeling further reduces confusion, separate storage prevents grabbing the wrong bottle, and a clinician double-check acts as a final safeguard before the patient receives the drug.

The other options don’t represent the same well-documented LASA risk, and the suggested mitigations aren’t as specifically aligned with preventing name confusion. For example, standard dosing alerts address dose errors rather than mix-ups from similar drug names, and color-coded labeling isn’t as consistently endorsed as a LASA-specific strategy.